Richard Saintvilus

This is no longer the very "cheap" territory, but given management commitment towards long-term growth, share buybacks and dividends, there are much more risky bets out there.

Value has never been the problem. But Microsoft has more work to do to change sentiment. Hopefully, its future gets more cloudy.

Investors shouldn't be fooled by the Street's reaction. This has all the makings of a trap.

Though the shares have been on a considerable run, the stock still doesn't look too expensive.

Pfizer's declining revenue hardly qualifies as kingpin status. But with the company's continued improvements and solid pipeline, the crown is within its grasp.

If management can figure out a way to get margins going again, while improving the medical devices business, I don't see any reasons why JNJ can't continue to rise. But those are two big "ifs.

I don't see much upside from here until management can realize more value and prove to investors that the company's brand actually means something again.

These shares have been undervalued for some time and should be acquired by investors who believe in the long-term growth prospects of mobile.

The company has to convince the likes of Samsung and Apple that its superior technology can make a difference to lower-priced rivals.

I don't think investors can know the extent of a recovery for at least a couple more quarters. But so long as Ciena's margins continue to improve, the risk is palatable.

The stock is cheap, but there's no compelling reason to buy here.

While $800 seems like a high price tag, Google wears it well.

I like SAP's business and I think the company has an excellent management team. I'd feel much better if the company can get operating margin to pick up again.

While there are some causes for concern, there is an equal amount to be optimistic about. And the bottom for this stock may hinge on whichever news surfaces last.

Just on modest free-cash-flow growth assumptions of 3%, these shares are worth at least $25.

Weak operating leverage is one area of concern. And for this stock to make any sense, salesforce.com has to differentiate itself from rivals.

The stock is not cheap, but there's still tremendous value to come.

It's going to require a strong stomach to buy this stock, and it requires more than 20/20 vision to see the glass-half-full side of this story.

The irony with iPrefs is that it truly belongs in Apple's product portfolio -- it's just as innovative.

Alcoa's investors should not ignore an opportunity to buy at significantly discounted rates.